A review of prescribing data shows that utilization of GLP-1 receptor agonists more than doubled between 2017 and 2022. The finding highlights a significant shift in treatment patterns during that five-year period.
Data covering the years 2017 through 2022 reveal that the use of GLP-1 receptor agonists more than doubled. The increase represents a growth of over 100 percent in the number of patients receiving these medications over that five-year span. This trend was documented across the period from 2017 to 2022.
The more-than-doubling figure indicates that by 2022, at least twice as many individuals were prescribed GLP-1 receptor agonists compared to 2017. The rate of uptake accelerated steadily over the five years. The finding is based on an analysis of prescribing patterns during that specific timeframe.
A doubling in use over five years suggests a meaningful change in how clinicians approach treatment. The growth occurred entirely within the 2017 to 2022 window. No data beyond that range was included in the report. The exact patient populations and regional variations are not specified in the available information.
In summary, the use of GLP-1 receptor agonists more than doubled from 2017 to 2022. That is the core fact from the analysis. The increase underscores a notable expansion in the adoption of this drug class over the five-year study period.
, -
Peptides referenced: GLP-1.
Related reading: Novo Nordisk Lawsuit Alleges Eli Lilly GLP-1 Ads Are Misleading, GLP-1 Finding Warned by Doctors May Increase Smell Loss Risk, Pharma Giants Dispute Over Obesity Drug Advertising, Wegovy Maker Files Suit Against Eli Lilly Over False GLP-1 Ads.